Technical Analysis for ARCT - Arcturus Therapeutics Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Outside Day | Range Expansion | -2.83% | |
| Wide Bands | Range Expansion | -2.83% | |
| Down 3 Days in a Row | Weakness | -2.83% | |
| Down 4 Days in a Row | Weakness | -2.83% | |
| Down 5 Days in a Row | Weakness | -2.83% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 10 hours ago |
| Down 3% | about 10 hours ago |
| Fell Below Previous Day's Low | about 10 hours ago |
| Down 2 % | about 10 hours ago |
| Up 1% | about 11 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 08/05/2024
Arcturus Therapeutics Ltd. Description
Alcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine. MDX consists of a single bi-layer oral tablet, which includes both a rapid onset release metadoxine formulation and a slow release metadoxine formulation together providing the desired dual release profile. The new extended-release formulation prolongs the human plasma levels of metadoxine for up to 12 hours, which results in enhanced efficacy benefits. ADAIR is an oral, semi-solid, liquid-filled, hard gelatin capsule of an abuse-deterrent IR formulation of dextroamphetamine sulfate, which is manufactured as 10 mg capsules.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Health Sciences Drugs Pharmacology Euphoriants Amphetamine Cognitive Disorders Glutamate Tablet Adhd Taar1 Agonists
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 45.0 |
| 52 Week Low | 17.5238 |
| Average Volume | 613,384 |
| 200-Day Moving Average | 29.59 |
| 50-Day Moving Average | 30.05 |
| 20-Day Moving Average | 30.87 |
| 10-Day Moving Average | 25.87 |
| Average True Range | 2.21 |
| RSI (14) | 33.33 |
| ADX | 28.08 |
| +DI | 17.80 |
| -DI | 34.41 |
| Chandelier Exit (Long, 3 ATRs) | 38.38 |
| Chandelier Exit (Short, 3 ATRs) | 29.88 |
| Upper Bollinger Bands | 43.56 |
| Lower Bollinger Band | 18.19 |
| Percent B (%b) | 0.22 |
| BandWidth | 82.15 |
| MACD Line | -2.34 |
| MACD Signal Line | -1.46 |
| MACD Histogram | -0.8849 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 25.82 | ||||
| Resistance 3 (R3) | 25.93 | 25.31 | 25.46 | ||
| Resistance 2 (R2) | 25.31 | 24.76 | 25.26 | 25.34 | |
| Resistance 1 (R1) | 24.49 | 24.42 | 24.18 | 24.38 | 25.22 |
| Pivot Point | 23.87 | 23.87 | 23.72 | 23.82 | 23.87 |
| Support 1 (S1) | 23.05 | 23.32 | 22.74 | 22.94 | 22.10 |
| Support 2 (S2) | 22.43 | 22.98 | 22.38 | 21.98 | |
| Support 3 (S3) | 21.61 | 22.43 | 21.86 | ||
| Support 4 (S4) | 21.50 |
